BMEA (Biomea Fusion) ROE % Adjusted to Book Value: -34.82% (As of Mar. 2026)


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.41
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion ROE % Adjusted to Book Value?

Biomea Fusion BMEA +7.22% 31 ROE % Adjusted to Book Value is -34.82% as of Mar. 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Biomea Fusion's ROE % for the quarter that ended in Mar. 2026 was -205.76%. Biomea Fusion's PB Ratio for the quarter that ended in Mar. 2026 was 5.91. Biomea Fusion's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -34.82%.

Biomea Fusion ROE % Adjusted to Book Value Related Terms

Biomea Fusion ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion ROE % Adjusted to Book Value Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -37.35 -24.77 -27.41 -45.93 -50.28

Biomea Fusion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -104.85 -77.42 -39.47 26.96 -34.82

BMEA vs ANIX, PMN, ATRA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Biomea Fusion's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's ROE % Adjusted to Book Value falls into.


BMEA
31GF Score
Biomea Fusion Inc BMEA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion ROE % Adjusted to Book Value Calculation

Biomea Fusion's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-152.35% / 3.03
=-50.28%

Biomea Fusion's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-205.76% / 5.91
=-34.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -34.82% mean?
Biomea Fusion (BMEA) has a ROE % Adjusted to Book Value of -34.82% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biomea Fusion and its competitors.
Is Biomea Fusion's ROE % Adjusted to Book Value too high?
Biomea Fusion's current ROE % Adjusted to Book Value is -34.82%. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's ROE % Adjusted to Book Value compare to ANIX and PMN?
Biomea Fusion's ROE % Adjusted to Book Value of -34.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biomea Fusion and its competitors. Biomea Fusion's current ROE % Adjusted to Book Value is -34.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current ROE % Adjusted to Book Value of -34.82%. The current ROE % Adjusted to Book Value is -34.82%. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current ROE % Adjusted to Book Value is -34.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.41
Price